If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Central memory T cells (TCM cells) express CD45RO, C-C chemokine receptor type 7 (CCR7), and L-selectin (CD62L). Central memory T cells also have intermediate to high expression of CD44. This memory subpopulation is commonly found in the lymph nodes and in the peripheral circulation. (Note- CD44 expression is usually used to distinguish murine naive from memory T cells). Effector memory T cells (TEM cells and TEMRA cells) express CD45RO but lack expression of CCR7 and L-selectin. They also have intermediate to high expression of CD44. These memory T cells lack lymph node-homing receptors and are thus found in the peripheral circulation and tissues. TEMRA stands for terminally differentiated effector memory cells re-expressing CD45RA, which is a marker usually found on naive T cells. Tissue-resident memory T cells (TRM) occupy tissues (skin, lung, etc.) without recirculating. One cell surface marker that has been associated with TRM is the intern αeβ7, also known as CD103. Virtual memory T cells (TVM) differ from the other memory subsets in that they do not originate following a strong clonal expansion event. Thus, although this population as a whole is abundant within the peripheral circulation, individual virtual memory T cell clones reside at relatively low frequencies. One theory is that homeostatic proliferation gives rise to this T cell population. Although CD8 virtual memory T cells were the first to be described, it is now known that CD4 virtual memory cells also exist.
The Beltrán-Leyva Cartel was founded by the four Beltrán Leyva brothers: Marcos Arturo, Carlos, Alfredo and Héctor. In 2004 and 2005, cartel leader Arturo Beltrán Leyva led groups of enforcers to compete for trafficking routes in northeastern Mexico against the Sinaloa Cartel. The Beltrán-Leyva Cartel infiltrated Mexico's political, judicial, and police institutions, including the Interpol in Mexico, to feed classified information about anti-drug operations against its rivals. Following the 2009 killing of Arturo Beltrán Leyva, the cartel entered into an internal power struggle between Arturo's brother, Héctor Beltrán Leyva, and his top enforcer Edgar Valdez Villarreal. Meanwhile, the cartel continued to dissolve with factions such as the South Pacific Cartel, La Mano Con Ojos, Independent Cartel of Acapulco, and La Barredora forming and the latter two cartels starting yet another intra-Beltrán Leyva Cartel conflict. The Mexican Federal Police considers the cartel to have been disbanded, and their last leader, Héctor Beltrán Leyva, was captured in October 2014.
== External links == Vincent du Vigneaud on Nobelprize.org including the Nobel Lecture, December 12, 1955 A Trail of Sulfa Research: From Insulin to Oxytocin https://weill.cornell.edu/archives/pdf/personal_aids/DuVigneaud.pdf
=== Pharmacodynamics === Tapentadol is a synthetic opioid with a dual mechanism of action: it acts as a full agonist of the μ-opioid receptor (MOR) and as a norepinephrine reuptake inhibitor (NRI). This unique pharmacological profile allows it to treat both nociceptive and neuropathic pain, and it is theorised that the effects on norepinephrine are a substantial benefit for people taking it. Tapentadol does not affect serotonin, unlike tramadol, which prevents the reuptake of serotonin and norepinephrine, similarly to certain antidepressants known as serotonin–norepinephrine reuptake inhibitors (SNRIs), such as desvenlafaxine and duloxetine. Tapentadol exhibits high binding selectivity and affinity for MOR, which is the principal target of the endogenous neuropeptide β-endorphin. It has significantly lower affinity for the δ-opioid receptor (DOR), κ-opioid receptor (KOR) and M1 as an antimuscarinic effect. MOR binding sites are distributed throughout the human brain, with higher densities in regions such as the amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and select cortical areas. Opioids like tapentadol are believed to mediate analgesia primarily through MOR activation in the midbrain periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), thereby inhibiting ascending pain pathways. MOR activation in the intestine contributes to common opioid-related side effects such as constipation. As noted, tapentadol is structurally similar to tramadol, and both drugs utilize a dual mechanism involving the opioid and norepinephrine systems.
In September 2024, the US FDA approved pembrolizumab with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. In March 2025, the US FDA granted traditional approval to pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1). Pembrolizumab previously received accelerated approval for this indication in May 2021. Efficacy was evaluated in KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 698 participants with HER2-positive advanced gastric or GEJ adenocarcinoma not previously treated with systemic therapy for metastatic disease. Among the 698 participants, 594 (85%) had tumors expressing PD-L1 with a CPS ≥1 using the PD-L1 IHC 22C3 pharmDx kit. Participants were randomized (1:1) to pembrolizumab 200 mg or placebo, in combination with trastuzumab and either fluorouracil plus cisplatin or capecitabine plus oxaliplatin. In June 2025, the US FDA approved neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma.
Sources: en.wikipedia.org
Furikake (振り掛け, ふりかけ, 振掛け, 振掛) is a dry Japanese condiment sprinkled on top of cooked rice, or used as an ingredient in onigiri. It typically consists of a mixture of dried fish or freeze-dried eggs, sesame seeds, dried seaweed flakes, sugar, and salt. Other ingredients, such as katsuobushi (sometimes indicated on the package as bonito), okaka (bonito flakes moistened with soy sauce and dried again), freeze-dried salmon particles, shiso, egg, powdered miso, or vegetables, are often added. Furikake is often brightly colored and flaky. It can have a slight fish or seafood flavoring and may be spicy or sweet. It can be used in Japanese cooking for pickling and for rice balls (onigiri).
=== Incandescent lamps === 'Black light' incandescent lamps are also made from an incandescent light bulb with a filter coating which absorbs most visible light. Halogen lamps with fused quartz envelopes are used as inexpensive UV light sources in the near UV range, from 400 to 300 nm, in some scientific instruments. Due to its black-body spectrum a filament light bulb is a very inefficient ultraviolet source, emitting only a fraction of a percent of its energy as UV, as explained by the black body spectrum.
=== Athletes === Australian swimmer and Olympic medalist James Magnussen said in February 2024 that he would end his retirement to compete in the games in an attempt to break the 50 m freestyle world record. D'Souza pledged a US$1 million prize if he did break it, and Magnussen said that he will "... juice to the gills ... break it in six months". He also said that the money could set him up for the next decade, that sport is about entertainment and is sometimes taken too seriously, and "This is not for everyone, and it is certainly not something for young athletes." According to Magnussen, as of May 2025 the performance-enhancing drugs he has taken include testosterone, BPC-157, CJC-1295, ipamorelin and thymosin. In May 2025, TEG announced that Greek swimmer Kristian Gkolomeev had unofficially broken the long course 50 metres freestyle world record at a February 2025 private event, beating Magnussen to the record and winning the $1 million prize. He reportedly swam the course in 20.89 seconds, 0.02 seconds faster than the record held by César Cielo. The performance-enhancing drugs he used, if any, were not disclosed. Other swimmers to join TEG included American Megan Romano, the first female participant, Ukrainian Andriy Govorov, as of 2026 the world record holder of the 50 m butterfly (long course), and Bulgarian Josif Miladinov. In September 2025, British swimmer and 2024 Olympic 50m freestyle silver medallist Ben Proud announced he would be joining TEG. Also in September, TEG announced that American sprinter and 2022 100 m world champion Fred Kerley will be competing.
PLGA is typically synthesized by ring-opening polymerization of the cyclic dimers lactide and glycolide, a method widely used because it allows better control over molecular weight and copolymer composition than direct condensation methods. Other reports show direct polycondensation of lactic acid and glycolic acid as another method, but this approach gives lower molecular weight material and is less suitable for producing controlled, high-performance PLGA grades. Common catalysts include tin(II) 2-ethylhexanoate and related organometallic catalysts, which are widely used in melt polymerization because of their activity and practical availability.
The Arizona softball team is among the top programs in the country. The softball team has won eight NCAA Women's College World Series titles, in 1991, 1993, 1994, 1996, 1997, 2001, 2006 and 2007 under head coach Mike Candrea (NCAA Softball Championship). The team has appeared in the NCAA National Championship in 1991, 1992, 1993, 1994, 1995, 1996, 1997 1998, 2001, 2002, 2006, 2007 and 2010 (a feat second only to UCLA), and has reached the College World Series 19 times. The Arizona Wildcats softball team won their first Pac-12 Championship in ten years after defeating the No. 12 UCLA Bruins 7–2, and qualified for its 31st consecutive NCAA tournament, creating a new NCAA softball record. Coach Candrea, along with former Arizona pitcher Jennie Finch, led the 2004 U.S. Olympic softball team to a gold medal in Athens, Greece. The Wildcat softball team plays at Rita Hillenbrand Memorial Stadium.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.